Microangiopathic Hemolytic Anemia in Pregnancy

Area of Science:

• Hematology
• Obstetrics
• Nephrology

Background:

• Thrombotic microangiopathies (TMAs) present with microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
• In pregnancy, TMAs can be pregnancy-related (e.g., preeclampsia, HELLP syndrome) or pregnancy-associated (thrombotic thrombocytopenic purpura [TTP], complement-mediated hemolytic uremic syndrome [CM-HUS]).
• Distinguishing between these TMA types is crucial as diagnostic features can overlap with pregnancy complications, potentially delaying recognition.

Purpose of the Study:

• To differentiate pregnancy-related TMAs from pregnancy-associated TMAs (TTP and CM-HUS).
• To highlight diagnostic challenges and optimal management strategies for TMAs in pregnancy.
• To discuss the role of ADAMTS13 analysis and complement inhibitor therapy.

Main Methods:

• Review of clinical presentations and diagnostic criteria for various TMAs in pregnancy.
• Analysis of treatment modalities, including plasma exchange, delivery, and complement inhibitors.
• Examination of timing of presentation and outcomes in subsequent pregnancies.

Main Results:

• Pregnancy-associated TMAs (TTP, CM-HUS) can present anytime during pregnancy, with TTP often in the third trimester and CM-HUS postpartum, though variations occur.
• Pregnancy-related TMAs typically manifest in the second or third trimester.
• ADAMTS13 testing is vital for diagnosing TTP, and complement inhibitors are effective for CM-HUS, reducing renal failure risk.

Conclusions:

• Accurate diagnosis of TMAs in pregnancy is critical for appropriate management, distinguishing between pregnancy-related and pregnancy-associated conditions.
• Plasma exchange is the primary treatment for TTP and other pregnancy-associated TMAs, while complement inhibitors are indicated for CM-HUS.
• Subsequent pregnancies can be managed safely following appropriate treatment for TTP and CM-HUS.